Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + albumin-bound paclitaxel + trastuzumab neoadjuvant study in HER2-positive breast cancer
ChiCTR2100047086Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib, paclitaxel and trastuzumab in breast cancer, sponsored by West China Hospital of Sichuan University. Primary endpoint: Pathological complete response rate. Started Dec 2020; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100047086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047086.